Management Team

Ms. Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Ms. Zannes founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental, and energy fields. In her current capacity as bioAffinity Technologies CEO and President, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics. Previously, Ms. Zannes was President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Ms. Zannes also served as a project manager at Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated, and financed the company’s renewable energy generation facilities. Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. Before entering the business world, she served as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX). She is licensed to practice law in New Mexico. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from the WTE Council of Columbia University. She is the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.

Dr. Rebel is a cancer (stem) cell biologist, with more than 20 years of experience in scientific research, focused on understanding the molecular events that lead to cancer development. She received her M.D. and Ph.D. from the Fre University in Amsterdam, The Netherlands, and post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. From 2005 to 2016, she led her own research group at The University of Texas (UT) Health Science Center at San Antonio, where she first collaborated with bioAffinity. Dr. Rebel received the 2012 Cancer Therapy and Research Center Discovery of the Year Award. She is the (co)author of more than 40 publications in peer-reviewed journals.

Mr. Dougherty has more than 20 years of experience in financial management and business strategy Most recently, Mr. Dougherty was Chief Financial Officer of  Amazon’s Alexa Commercial Domains, where he was responsible for financial strategy over Alexa’s multi-billion-dollar investments in AI-generated customer experiences. Previously, Mr. Dougherty was Chief Financial and Operating Officer of TINT, a user-generated content platform, and Chief Financial Officer at Filestack, a secure file handling service provider that was acquired by Idera, Inc. Prior to that, Mr. Dougherty served as Chief Financial Officer for Amazon Pay, where he supported Amazon’s digital payment wallet globally. Earlier in his career Mr. Dougherty held various finance positions at Russell Investments and Medisystems Corporation. He is a certified public accountant and a Chartered Global Management Accountant by the American Institute of Certified Public Accountants.

Mr. Reveles brings more than 25 years of experience as a clinical geneticist skilled in the creation and management of CLIA clinical laboratories, coding and CPT reimbursement valuations. Mr. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics. He was Laboratory Director for OncoPath Laboratory – START Cancer Center in San Antonio, Texas. Mr. Reveles is (co)author of 15 publications and three abstracts in peer-reviewed journals. He earned his Master’s Degree in biology/genetics from the University of The Incarnate Word in San Antonio, Texas.

Mr. Coleman has more than 15 years’ experience in medical sales and marketing where he has succeeded in launching new products to the healthcare market, driving business development and strong client relationships, and implementing strategic sales initiatives. Prior to joining bioAffinity Technologies, he was executive account manager for the respiratory portfolio of Olympus America’s therapeutic solutions division. At Olympus, a leading global medtech company, Mr. Coleman worked primarily with pulmonologists, thoracic surgeons and physicians treating patients with lung disease. Earlier in his career, he held sales management positions at Caldera Medical, a medical device company focused on women’s health, and Ecolab, a global sustainability leader providing water, hygiene and hospital infection prevention solutions and services.

Dr. Bauta is a medicinal chemist with more than 25 years of experience in discovery, development, and commercialization of pharmaceuticals to treat oncology, virology, neuroscience, immunology, and metabolic diseases. He joined bioAffinity Technologies from Southwest Research Institute where he helped develop the Institute’s pharmaceuticals services and bioengineering business. Dr. Bauta was Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development, and FDA approval of multiple therapeutics. He holds several patents and has published in the journal Science and more than a dozen other scientific journals and conference proceedings. Dr. Bauta received his Ph.D. from the University of Chicago.

Dr. Elzi brings 20 years of research experience to bioAffinity where he leads research on the mechanism of porphyrin uptake in cancer cells that has resulted in therapeutic discoveries to selectively kill cancer without harm to normal tissue. Dr. Elzi earned his Ph.D. in Molecular and Cellular Biology from the University of Washington, in conjunction with the Fred Hutchinson Cancer Research Center. He subsequently performed post-doctoral research at the Bonfils Blood Center and University of Colorado Department of Surgery, where he studied the molecular mechanisms of transfusion-related lung injury. Dr. Elzi comes to bioAffinity from The UT Health Science Center where his research included applying proteomic techniques to study cellular senescence in primary and cancer cells. He has published more than 20 peer-reviewed articles.

Dr. Rebeles joined bioAffinity in 2019 as Director of Diagnostics where she led the team of scientists in the research and development of the company’s first product, CyPath® Lung, an automated flow cytometry tests that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Dr. Rebeles was a research scientist with the United States Air Force 59th Medical Wing for Science and Technology where she performed recurring analyses on research portfolios to identify critical gaps in military medicine and proposed new projects to address those needs. Prior to that, she served as the Flow Cytometry and Microarray Technical Director at the Greehey Children’s Cancer Research Institute of the University of Texas Health Science Center at San Antonio, TX. Dr. Rebeles received her Ph.D. in Nutritional Biochemistry from the University of North Carolina Chapel Hill Gillings School of Global Public Health with training in nutritional immunology by investigating the effects of obesity on the immune response to influenza infection.

Mr. Zannes has been corporate legal counsel to both public and private biomedical firms for more than 16 years, having begun his legal career as a sole practitioner accepting criminal, business, family, and tort litigation. Prior to receiving his J.D., Mr. Zannes was a court bailiff and ran his own private investigation firm after serving as an investigator for the Albuquerque City Attorney. He received his J.D. from the University of New Mexico School of Law and attended the New England Conservatory with studies in violin and saxophone. Mr. Zannes began his undergraduate education at The University of North Carolina where he was a student athlete on scholarship. In addition to his duties as General Counsel and Secretary, Mr. Zannes is responsible for corporate compliance and directs Human Resources. Mr. Zannes and Maria Zannes are siblings.